@article{9e5b1fbc4e004e13bb6fff5bf517999d,
title = "An update on recent developments and highlights in food allergy",
abstract = "While both the incidence and general awareness of food allergies is increasing, the variety and clinical availability of therapeutics remain limited. Therefore, investigations into the potential factors contributing to the development of food allergy and the mechanisms of natural tolerance or induced desensitization are required. In addition, a detailed understanding of the pathophysiology of food allergies is needed to generate compelling, enduring, and safe treatment options. New findings regarding the contribution of barrier function, the effect of emollient interventions, mechanisms of allergen recognition, and the contributions of specific immune cell subsets through rodent models and human clinical studies provide novel insights. With the first approved treatment for peanut allergy, the clinical management of food allergy is evolving towards less intensive, alternative approaches involving fixed doses, lower maintenance dose targets, co-administration of biologicals, adjuvants, and tolerance-inducing formulations. The ultimate goal is to improve immunotherapy and develop precision-based medicine via risk phenotyping allowing optimal treatment for each food-allergic patient.",
keywords = "barrier function, food allergy, immune response, immunotherapy, mouse models",
author = "Arielle Locke and Lisa Hung and Upton, {Julia E M} and Liam O'Mahony and Jennifer Hoang and Thomas Eiwegger",
note = "Funding Information: Arielle Locke, Lisa Hung, and Jennifer Hoang have nothing to disclose. Julia E.M. Upton reports grants/research support from DBV Technologies, Regeneron, CIHR, ALK‐Abell{\'o}, SickKids Food Allergy and Anaphylaxis Program, Advisory board for Pfizer, Bausch Health, and Food Allergy Canada; in‐kind drug donation from Novartis, other for Astra‐Zeneca, all outside the current work. Liam O'Mahony reports personal fees from PrecisionBiotics, grants from GSK, and Chiesi, outside the submitted work. He has contributed to company‐sponsored symposia for Nestle, Nutricia, Reckitt, and Abbott. Thomas Eiwegger reports to act as local PI for company sponsored trials by DBV Therapeutics, Greer Stallergens, and sub‐investigator for Regeneron and ALK‐Abell{\'o}. He is co‐investigator or scientific lead in three investigator‐initiated oral immunotherapy trials supported by the SickKids Food Allergy and Anaphylaxis Program and serves as an associate editor for Allergy. He/his laboratory received unconditional/in‐kind contributions from Macro Array Diagnostics and an unrestricted grant from ALK‐Abell{\'o}. He holds advisory board roles for ALK‐Abell{\'o}, VAMED, and Nutricia/Danone and Aimmune. Thomas Eiwegger reports lecture fees from Novartis, ThermoFisher, Nutricia/Danone, Aimmune, and ALK‐Abell{\'o}. Publisher Copyright: {\textcopyright} 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.",
year = "2023",
month = sep,
doi = "10.1111/all.15749",
language = "English",
volume = "78",
pages = "2344--2360",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "9",
}